SEP 04, 2018 6:53 PM PDT

Dopamine Provided Targeted Therapy for Neuropsychiatric Disorders

WRITTEN BY: Nouran Amin

Credit: PsyPost.com

According to a study published in Molecular Psychiatry, research scientists at Columbia University Vagelos College of Physicians and Surgeons have brought light on the mechanisms behind dopamine in relation to neuropsychiatric disorders. More specifically, on how dopamine receptors signal within cells. Such research has opened the door for more tolerable and targeted treatments.

The central nervous system's (CNS) dopamine receptors hold a crucial role in a broad array of neural processes, such as motor control, learning and memory, and reward. The purpose of the study was to focus on the dopamine D2 receptor (D2R) which serves as an important target in the treatment of disorders such as schizophrenia and Parkinson's disease. The drugs used to treat such conditions either “block or activate these receptors to address dysfunctional receptor signaling”. However, antipsychotic drugs that work on D2Rs can hold adverse side effects, including weight gain, involuntary movements, and decreased motivation.

Watch Video Below To Learn More About Dopamine:

Fortunately, researchers have discovered that D2Rs transmit signals through two mechanisms intracellular: 1. by activating G proteins or 2. by G-protein independent arrestin-signaling. Previous research on opioid receptors, for targeted pain relief, conclude that suggest that it “may be possible to maintain the therapeutic effects while avoiding negative side effects”, including respiratory depression, by G protein signaling pathway activation. "We asked whether these signaling pathways might also lead to different behavioral effects at the D2R, and whether this might provide a new approach to improved antipsychotic drugs with fewer side effects," explains Dr. Jonathan Javitch, Lieber Professor of Experimental Therapeutics in Psychiatry and professor of pharmacology at Columbia University Vagelos College of Physicians and Surgeons.

To find whether the two pathways regulate different behaviors, scientists analyzed mice that were designed to carry a mutated D2R that would only facilitate the arrestin pathway. In these mice, the mutant D2R brought back motor function just as the non-mutant D2R does, indicating that “arrestin recruitment can enhance motor function on its own”. "This finding was quite exciting as it indicates that the activational component of motivation that enhances locomotion is regulated by a different intracellular mechanism than the reward-driven directional component," says Dr. Christoph Kellendonk, associate professor of pharmacology (in Psychiatry) at Columbia University Vagelos College of Physicians and Surgeons. "For the former, arrestin signaling is sufficient whereas the latter requires activation of G-proteins."

"These results offer the exciting possibility that therapeutic approaches targeting specific D2R-mediated signaling pathways could not only treat psychosis but also avoid some of the adverse side effects experienced by patients taking the existing, less targeted medications," explains Javitch.

 

Source: Columbia University Irving Medical Center, Molecular Psychiatry

About the Author
  • Nouran earned her BS and MS in Biology at IUPUI and currently shares her love of science by teaching. She enjoys writing on various topics as well including science & medicine, global health, and conservation biology. She hopes through her writing she can make science more engaging and communicable to the general public.
You May Also Like
DEC 05, 2019
Drug Discovery & Development
DEC 05, 2019
New Injection that Treats Peanut Allergy
Peanut allergies affect between 1 and 3% of the US population. Associated with a heightened risk of severe anaphylactic reactions, oral immunotherapy is th...
DEC 09, 2019
Drug Discovery & Development
DEC 09, 2019
Could the diabetic drug 'metformin' extend a healthy lifespan?
The most commonly prescribed diabetic medication for the Type 2 condition is ‘Metformin’—a drug with a mysterious mechanism of action but...
DEC 11, 2019
Drug Discovery & Development
DEC 11, 2019
Drug To Treat Ulcerative Colitis
Biomedical researchers at the University of California—Riverside, found that the therapeutic drug ‘tofacitinib’ used in treating autoimmu...
DEC 18, 2019
Drug Discovery & Development
DEC 18, 2019
Stroke Drug Enhances Stem Cell Therapies for Spinal Cord Injuries
Using rat models of spinal cord injuries, Yasuhiro Shiga, MD, PhD, thought treating them with stem cell therapy would point to nowhere but the nature of re...
JAN 03, 2020
Drug Discovery & Development
JAN 03, 2020
New Drug Combo Reverses Breast Cancer
Researchers from Georgetown University have found that combining a drug used for epilepsy, bipolar disorder, and migraines with a drug used to ease blood p...
JAN 16, 2020
Cancer
JAN 16, 2020
FLASH proton therapy: faster and more effective
A new technique called FLASH proposes a new type of radiation therapy. The technique is composed of an ultra-high dose rate of radiotherapy and uses electr...
Loading Comments...